Clinical Guides
Interstitial Lung Disease
A clinically focused adult guide to interstitial lung disease in India, integrating exposure and autoimmune assessment, HRCT pattern recognition, multidisciplinary diagnosis, phenotype-directed treatment, antifibrotics, transplantation and evidence limitations.
MedNext Academy | 13 min read
Interstitial Lung Disease
A clinically focused adult guide to interstitial lung disease in India, integrating exposure and autoimmune assessment, HRCT pattern recognition, multidisciplinary diagnosis, phenotype-directed treatment, antifibrotics, transplantation and evidence limitations.
Summary
Interstitial lung disease is an umbrella term for heterogeneous disorders that injure the alveolar walls, interstitium, small airways or pulmonary vasculature and may produce inflammation, fibrosis, or both. A label of ILD is the beginning of diagnosis, not the endpoint. Clinicians must determine whether disease is caused by a connective-tissue disorder, inhaled antigen, occupation, medicine, radiation, infection or another systemic process before calling it idiopathic. The core assessment combines a meticulous temporal and exposure history, examination, full pulmonary function testing, resting and exertional oxygenation, and high-resolution CT acquired with an appropriate protocol. Serology, bronchoalveolar lavage, cryobiopsy or surgical biopsy are selective tests, not a universal checklist. Multidisciplinary discussion among an ILD-experienced respiratory physician, thoracic radiologist and, when tissue is available, pulmonary pathologist improves integration of discordant evidence. Treatment is phenotype and cause specific: remove harmful exposure; treat the underlying autoimmune or inflammatory disease when benefits outweigh risks; use antifibrotic therapy for idiopathic pulmonary fibrosis and selected progressive pulmonary fibrosis according to specialist guidance; and provide vaccination, rehabilitation, oxygen assessment and palliative support. Serial symptoms, forced vital capacity, diffusing capacity, exercise capacity and imaging establish trajectory. In India, tuberculosis must be excluded before immunosuppression, domestic and occupational exposures require locally intelligible questioning, and late referral can foreclose trial enrollment or transplantation. Evidence is strongest for defined IPF and progressive-fibrosis questions, and substantially weaker for many rare ILD subtypes.
How Common Is It?
There is no single prevalence for ILD because it includes more than a hundred disorders, classification evolves and case ascertainment depends on CT access and expert review. Idiopathic pulmonary fibrosis is uncommon but clinically important because it is relentlessly progressive in many patients. Connective-tissue disease-associated ILD, hypersensitivity pneumonitis, sarcoidosis, occupational pneumoconioses and drug-induced disease contribute differently across populations. The prospective ILD-India registry enrolled 1,084 adults from 27 centres in 19 cities between 2012 and 2015. Its multidisciplinary classification found hypersensitivity pneumonitis most frequently, followed by connective-tissue disease-associated ILD and IPF; however, correspondence about the registry highlighted exposure uncertainty, non-consecutive recruitment and referral selection. Those data are valuable evidence that Indian patterns may differ, but they are not a contemporary national prevalence survey and should not be converted into a claim that nearly half of all Indian ILD is hypersensitivity pneumonitis. District-level underdiagnosis, delayed HRCT, competing tuberculosis diagnoses and concentration of expertise in cities further distort observed proportions. For an individual clinician, prevalence informs prior probability but cannot replace phenotype. A dry cough, exertional breathlessness, inspiratory crackles, restrictive physiology or incidental interstitial abnormalities should trigger structured assessment. Even subtle disease matters when there is a high-risk connective-tissue disorder, fibrogenic occupational exposure or a familial pattern, because earlier characterization permits exposure removal, monitoring and timely specialist decisions.
Risk Factors
Risk assessment must be a lifetime inventory, not a single question about smoking. Ask about birds, feathers, mould, dampness, hay, grain, sugarcane residue, compost, mushrooms, humidifiers, evaporative air coolers and repeated water damage; record timing, intensity, co-exposures and whether symptoms change away from the setting. Occupational review should cover stone cutting, mining, quarrying, sandblasting, construction, foundries, ceramics, cement, asbestos handling, welding, metal or hard-metal dust, textile work, farming and pesticide aerosols. In India, workers may use informal job titles, change workplaces frequently or have unprotected home-based exposures, so describe tasks and materials rather than relying on industry labels. Review medicines including amiodarone, nitrofurantoin, methotrexate, bleomycin, immune checkpoint inhibitors and other cancer therapy, and record thoracic radiation. Ask about Raynaud phenomenon, inflammatory joints, proximal weakness, mechanics' hands, rashes, sicca, dysphagia and skin tightening; pulmonary disease can precede a classifiable connective-tissue disorder. Smoking increases IPF risk and is associated with specific smoking-related ILDs, while family history may indicate familial pulmonary fibrosis or a telomere disorder. Ageing, male sex and genetic susceptibility shape IPF probability but do not diagnose it. Infection risk, particularly tuberculosis, HIV and endemic fungi, becomes crucial before immunosuppression. Gastro-oesophageal reflux and microaspiration are common but causal and treatment relationships are uncertain. A credible exposure does not prove hypersensitivity pneumonitis, and absent recall does not exclude it; integrate exposure evidence with HRCT, lavage and multidisciplinary reasoning.
Diagnosis
History
Define onset and slope of exertional breathlessness, dry or productive cough, fatigue, fever, weight loss, haemoptysis, chest pain and acute deteriorations. Construct a chronological home, hobby, occupation, medicine, radiation and infection exposure record. Ask systemic autoimmune questions, previous tuberculosis, sleep symptoms, smoking and family history of fibrosis, premature greying, marrow failure or liver disease. Document baseline function and oxygen needs.
Examination
Measure respiratory rate and resting oxygen saturation, then assess exertional desaturation safely. Fine late-inspiratory basal crackles and clubbing support fibrotic disease but are not universal. Look for pulmonary hypertension, right-heart failure and respiratory muscle weakness. Examine skin, nails, joints, muscles, mouth, salivary features and vascular signs for connective-tissue disease. Identify work-related dust on clothing only as a clue, not proof of causation.
Investigations
Perform chest radiography, spirometry, lung volumes and diffusing capacity; restrictive physiology may be absent early, and obstruction can coexist. Use a standardized HRCT protocol with thin sections, inspiratory images, expiratory imaging when air trapping is relevant and prone views when dependent opacity is uncertain. Describe distribution and pattern rather than calling every reticulation IPF. Obtain targeted autoimmune serology with clinical interpretation. Test for TB or other infection before immunosuppression when epidemiology, symptoms or imaging warrant it. Echocardiography screens for pulmonary hypertension but right-heart catheterization confirms it when management depends on the result. Bronchoalveolar lavage cellular analysis, transbronchial cryobiopsy and surgical biopsy are selected after multidisciplinary review of diagnostic gain and procedural risk. MDD should assign confidence, identify unresolved alternatives and specify a monitoring plan when diagnosis remains unclassifiable.
Differential Diagnosis
The first distinction is true diffuse parenchymal disease versus mimics. Pulmonary oedema, atypical infection, miliary or fibrotic tuberculosis, lymphangitic malignancy, diffuse alveolar haemorrhage and drug toxicity can produce bilateral interstitial opacity. Chronic airway disease with air trapping, bronchiectasis, obesity-related restriction, neuromuscular weakness and pulmonary vascular disease may explain breathlessness or abnormal physiology without primary ILD. Within ILD, separate known-cause disease from idiopathic interstitial pneumonias. Connective-tissue disease-associated patterns include nonspecific interstitial pneumonia, organizing pneumonia and usual interstitial pneumonia; clinical phenotype matters more than pattern alone. Hypersensitivity pneumonitis depends on the relationship among exposure, HRCT features such as mosaic attenuation or the three-density pattern, bronchoalveolar lavage lymphocytosis and pathology. Pneumoconioses follow exposure and characteristic radiology but may coexist with TB. Sarcoidosis, eosinophilic lung disease, pulmonary Langerhans cell histiocytosis, lymphangioleiomyomatosis and pulmonary alveolar proteinosis have distinguishing clinical and imaging features. IPF requires exclusion of other causes and an appropriate UIP framework; honeycombing is not synonymous with IPF because UIP occurs in rheumatoid disease, chronic hypersensitivity pneumonitis, asbestosis and other conditions. An acute worsening requires evaluation for infection, pulmonary embolism, pneumothorax, heart failure, aspiration and treatment toxicity before diagnosing an acute exacerbation. In India, empirically treating every diffuse opacity as TB or every fibrotic pattern with corticosteroids risks harm. Unclassifiable ILD is an honest conclusion when data remain discordant or biopsy risk outweighs likely diagnostic gain.
Management
Begin by naming the likely cause, inflammatory activity, fibrotic burden, current severity and trajectory. Remove a credible inhaled antigen or occupational exposure and document whether removal is practically achievable; involve occupational health and advise workplace controls rather than transferring all responsibility to the worker. Stop a causative medicine with specialist input and treat the underlying connective-tissue disease collaboratively with rheumatology. Immunosuppression may help selected inflammatory ILDs, but the agent, induction versus maintenance strategy and monitoring differ across diagnoses; corticosteroids are not generic treatment for established IPF and can worsen unrecognized infection. For IPF, offer disease education and discuss licensed antifibrotic therapy early. For non-IPF ILD that meets progressive pulmonary fibrosis criteria despite appropriate standard management, nintedanib may be considered; pirfenidone evidence remains less certain in this broad group. Neither drug reverses fibrosis, and slowing FVC decline is not equivalent to symptom cure or guaranteed survival. Provide smoking cessation, influenza, pneumococcal and other indicated vaccination, pulmonary rehabilitation, nutrition support and advance care planning. Assess ambulatory and long-term oxygen against documented hypoxaemia and local policy, recognizing limited ILD-specific outcome evidence. Treat comorbid sleep-disordered breathing, cardiovascular disease, reflux symptoms, anxiety and depression without assuming they caused fibrosis. Monitor symptoms, FVC, DLCO, exercise oxygenation, adverse effects and HRCT when it will change management. Refer early for trials and lung transplantation; a late referral made only after profound deconditioning may remove options.
Prescribing Information
Nintedanib and pirfenidone are specialist antifibrotics used principally for IPF; nintedanib also has guideline support for selected adults with progressive pulmonary fibrosis other than IPF. Confirm the diagnostic and progression criteria before prescribing, discuss realistic goals, obtain baseline liver tests and review pregnancy potential, bleeding risk, cardiovascular history, interactions and organ function. Diarrhoea, nausea, appetite or weight loss and liver-enzyme elevation are common practical barriers with nintedanib; dose interruption, reduction and supportive treatment may preserve adherence. Pirfenidone commonly causes gastrointestinal intolerance, anorexia, fatigue, photosensitivity and liver abnormalities; advise sun protection and follow product-specific titration and monitoring. Do not invent dose schedules from memory: use the current Indian product information, institutional protocol and regulatory indications because formulations and access can differ. Immunomodulation must match phenotype. Options used in connective-tissue or inflammatory ILD include glucocorticoids, mycophenolate, azathioprine, cyclophosphamide, rituximab or other agents, but comparative evidence, dosing and toxicity vary. Screen for active TB and other relevant infection before substantial immunosuppression, update vaccines when feasible, consider Pneumocystis prophylaxis according to regimen and host, and monitor blood counts, renal and liver function. Avoid the former prednisone-azathioprine-N-acetylcysteine combination in IPF. Routine antacid medication or antireflux surgery solely to improve respiratory outcomes in IPF is not recommended by the 2022 guideline, although symptomatic reflux can still be treated for gastrointestinal indications. Prescribing should be shared with an ILD service, with explicit stop, toxicity and pregnancy plans.
When to Refer
Refer suspected ILD to a respiratory service with HRCT and multidisciplinary capability rather than starting months of empirical steroids. Urgency increases with resting or exertional hypoxaemia, rapid symptom progression, falling FVC or DLCO, extensive fibrosis, pulmonary hypertension, recurrent acute deteriorations, significant haemoptysis or diagnostic uncertainty about infection and malignancy. Rheumatology input is required for systemic features, disease-specific autoantibodies or a CTD pattern even when classification is incomplete. Occupational-medicine referral helps document exposure, advise workplace modification and address compensation or surveillance without delaying clinical care. Discuss bronchoscopy or biopsy at MDD when the result is likely to change treatment and procedural risk is acceptable; refer to an experienced centre for cryobiopsy rather than treating it as routine bronchoscopy. Transplant referral should be early for radiographic or histological UIP, FVC below about 80% predicted, DLCO below about 40% predicted, any oxygen requirement, disease-related functional limitation, or inflammatory ILD failing an appropriate therapy trial, in line with ISHLT consensus. These are referral prompts, not automatic listing rules. Listing depends on progression, hospitalizations, functional decline, desaturation, pulmonary hypertension, comorbidity and programme assessment. Indian access to transplant and antifibrotics is geographically and financially uneven, making early discussion, transparent cost counselling and referral to a feasible centre especially important. Palliative-care referral can run alongside disease-modifying assessment for refractory breathlessness, cough, fatigue, anxiety and future planning; it is not restricted to the final days.
Red Flags
New severe breathlessness, tachypnoea, cyanosis, altered mental state, hypotension or rapidly increasing oxygen need requires emergency assessment. In a patient with known ILD, acute diffuse ground-glass opacity is not automatically an acute exacerbation: urgently evaluate infection including TB where relevant, pulmonary embolism, oedema, aspiration, pneumothorax, alveolar haemorrhage, acute cardiac disease and drug toxicity. Haemoptysis, unilateral pleuritic pain, asymmetric leg swelling, fever with immunosuppression and new focal consolidation are particularly important clues. A fall in oxygen saturation on minimal exertion, rapidly decreasing FVC or DLCO, new syncope, raised jugular venous pressure, oedema or a loud pulmonary component suggests advanced disease or pulmonary hypertension and should accelerate referral. Immunosuppressant toxicity may present with fever, oral ulcers, cytopenia, jaundice, kidney injury or opportunistic infection; antifibrotic toxicity includes persistent diarrhoea, marked weight loss, liver injury and bleeding concerns. A patient on amiodarone, nitrofurantoin, checkpoint inhibition or cytotoxic therapy with new infiltrates needs prompt medicine review and coordinated management. Before escalating corticosteroids, collect appropriate infectious samples when safe because treatment can obscure TB and worsen uncontrolled infection. Red flags in the diagnostic process include an HRCT report that names IPF without exposure or autoimmune exclusion, discordant radiology and clinical data, and biopsy proposed without asking whether it would alter care. Rapid progression should trigger simultaneous stabilization, diagnostic reassessment, transplant discussion where appropriate and symptom support rather than a single sequential pathway.
Indian Clinical Context
Indian practice requires unusually careful separation of ILD from tuberculosis and post-TB structural lung disease. Chronic cough, weight loss, upper-zone change, nodules, cavities, nodes or immunosuppression should prompt microbiological TB investigation using a WHO-recommended rapid diagnostic strategy; neither a negative smear nor a steroid response is adequate exclusion. Domestic exposure questions should name pigeons, poultry, feather bedding, mould, damp rooms, evaporative air coolers, stored grain and agricultural residue, then establish dose and temporality. Workplace histories must include stone and engineered-stone cutting, mining, quarrying, sandblasting, construction, ceramics, cement, asbestos, welding, foundry and textile tasks, including informal and home-based work. Ask what dust control and respiratory protection actually occur. The ILD-India registry established the feasibility and value of MDD across centres, but its high hypersensitivity-pneumonitis proportion has legitimate uncertainty and should not anchor every patient. Access constraints may limit prone or expiratory HRCT, DLCO, bronchoalveolar lavage, pathology review, antifibrotics and transplant. Record what was unavailable and use remote radiology or regional MDD where possible instead of implying diagnostic certainty. Treatment cost, travel, heat, nutrition and diarrhoea can undermine antifibrotic adherence; proactive monitoring and a written contact plan matter. Do not substitute repeated empirical antibiotics, anti-TB therapy or corticosteroids for referral. Occupational exposure reduction may require employer engagement and social support, not advice to abandon income. India-specific outcome evidence for many subtypes, oxygen strategies and transplant access remains incomplete, so explain when recommendations are extrapolated from international populations.
NMC Competency Mapping
This guide supports the NMC graduate in structured evaluation of chronic respiratory symptoms and restrictive lung disease under supervision. A learner should obtain an occupational, environmental, medicine, autoimmune, smoking, family and infection history; perform general and respiratory examination; recognize clubbing, fine inspiratory crackles, hypoxaemia and right-heart strain; and describe how ILD differs from airway or pleural disease. Investigation competence includes interpreting chest radiography, spirometry, lung volumes, diffusing capacity and exercise desaturation, while explaining why HRCT technique and pattern distribution matter. The learner should formulate a prioritized differential that includes TB, infection, connective-tissue disease, hypersensitivity pneumonitis, pneumoconiosis, drug toxicity, sarcoidosis and idiopathic fibrotic disease. They should understand that MDD integrates clinical, radiological and pathological evidence and that lung biopsy is selective. Management objectives include exposure avoidance, smoking cessation, vaccination, rehabilitation, oxygen assessment, monitoring and timely referral. Pharmacology teaching should contrast antifibrotic treatment with immunosuppression, identify major toxicities, and reject routine corticosteroids as treatment for IPF. Professional competencies include communicating diagnostic uncertainty, explaining long-term monitoring, respecting occupational and financial constraints, and obtaining informed consent for invasive tests. Students should recognize emergency deterioration and infection risk before immunosuppression. Procedures, definitive subtype diagnosis, antifibrotic initiation and transplant listing require specialist supervision. Map workplace teaching to current institutional competency codes and assessment methods, because a national curriculum defines outcomes but local logbooks determine how history, examination, interpretation and escalation are observed.
Key Exam Pearls for NEET PG
ILD is a syndrome; IPF is one diagnosis within it. Usual interstitial pneumonia on HRCT is characterized by basal and subpleural-predominant reticulation with traction bronchiectasis and, in a definite pattern, honeycombing; alternative features should redirect the differential. UIP is not pathognomonic of IPF and can occur in rheumatoid arthritis, chronic hypersensitivity pneumonitis and asbestosis. Nonspecific interstitial pneumonia commonly shows bilateral ground-glass and fine reticulation with relative subpleural sparing, particularly in connective-tissue disease. Hypersensitivity pneumonitis reasoning combines antigen exposure, small-airway features, mosaic attenuation or the three-density pattern, lavage lymphocytosis and pathology; no single element is always mandatory. Spirometry typically shows restriction with reduced FVC, but early disease can have preserved volumes; DLCO may fall earlier and combined emphysema can mask restriction. Diagnose IPF only after excluding known causes and using MDD when uncertainty remains. Progressive pulmonary fibrosis in non-IPF ILD requires worsening in at least two of three domains—symptoms, radiological progression and physiological progression—within the specified interval and without another explanation. Nintedanib has a conditional recommendation for PPF; antifibrotics slow decline rather than regenerate lung. Avoid the prednisone-azathioprine-N-acetylcysteine combination in IPF. Acute deterioration is a diagnosis of exclusion. In India, exclude TB before immunosuppression and obtain task-based occupational exposure history. Early transplant referral is appropriate in UIP, oxygen requirement or significant physiological impairment; referral is distinct from listing. MDD and longitudinal behavior are high-yield answers when a single test does not resolve subtype.
Frequently Asked Questions
Does a usual interstitial pneumonia pattern always mean idiopathic pulmonary fibrosis?
No. UIP is a radiological or pathological pattern that can occur in IPF, connective-tissue disease, chronic hypersensitivity pneumonitis, asbestosis and other conditions. IPF is diagnosed only after known causes have been excluded and the clinical context is concordant. An ILD multidisciplinary discussion should integrate exposure, autoimmune features, HRCT and any pathology. A report of honeycombing alone should not bypass this process, particularly in a high-TB-burden or occupational setting.
When are antifibrotic medicines used in interstitial lung disease?
Pirfenidone and nintedanib are established specialist options for IPF, subject to local authorization, contraindications and monitoring. The 2022 ATS/ERS/JRS/ALAT guideline conditionally supports nintedanib for selected non-IPF ILD meeting progressive pulmonary fibrosis criteria after appropriate standard management; evidence for pirfenidone in the broad PPF population is less certain. These medicines may slow physiological decline but do not reverse fibrosis. Diagnosis, trajectory, adverse effects, cost and patient priorities should be managed with an ILD service.
Is lung biopsy required to diagnose every interstitial lung disease?
No. A confident diagnosis may follow a characteristic clinical setting and HRCT pattern after multidisciplinary review. Bronchoalveolar lavage, cryobiopsy or surgical biopsy is considered when remaining uncertainty is important enough that the result is likely to change management and procedural risk is acceptable. Advanced age, severe physiological impairment, pulmonary hypertension and comorbidity can increase harm. Choosing observation with a documented working diagnosis and reassessment plan can be safer and more honest than pursuing tissue at any cost.
Why is tuberculosis testing important before ILD immunosuppression in India?
TB can mimic diffuse or fibrotic lung disease, coexist with structural lung abnormalities and reactivate during substantial immunosuppression. When symptoms, imaging, exposure or immune status make pulmonary TB plausible, obtain suitable respiratory material for a WHO-recommended rapid molecular test and further culture or resistance testing as indicated. A negative smear alone is insufficient. Testing should be proportionate rather than indiscriminate, and urgent respiratory compromise may require parallel stabilization and infection evaluation with specialist input.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic